Bextra stroke Pennsylvania

bextra

Bextra® stroke Pennsylvania. Speak to your doctor right away about alternatives to this drug if you are currently using it.

Withdrawal

On April 7, 2005 the FDA announced that it has asked Pfizer, Inc. to withdraw Bextra from the market "because the overall risk versus benefit profile for the drug is unfavorable."

Side Effects for Bextra or Valdecoxib include the following:

Potential for increased risk of cardiovascular events
Gastrointestinal bleeding
Serious skin reactions, some resulting in death.

For a free case evaluation from a Pennsylvania attorney, click here: http://www.lawforum.net/areas/bextra/pennsylvania/
Munley, Munley & Cartwright, P.C. is a Pennsylvania law office which has breaking news and information about this lawsuit http://www.munley.com/drugs/bextra.html
To read the FDA's announcement withdrawing Bextra
Click here to read the FDA questions and answers about strengthened warnings on Bextra® boxes http://www.fda.gov/cder/drug/infopage/bextra/bextraQA.htm
To report any unexpected adverse or serious events associated with the use of Bextra® contact the FDA MedWatch program at: 1-800-FDA-1088 or on the Internet at http://www.fda.gov/medwatch/index.html

What is Bextra?

Bextra® is a non-steroidal anti-inflammatory drug (NSAIDs), known as a COX-2 selective agent. It is prescribed for inflammation and pain from arthritis or menstrual cramping. Other drugs in this class include Celebrex® and Vioxx®. Bextra® and Celebrex® are both marketed by Pharmacia Corporation and Pfizer and Vioxx® is manufactured by Merck. Doctors switched patients from Vioxx® to Bextra® when Merck voluntarily removed it from the market due studies showing an increased risk for heart attack and stroke.

bextra site map

Autism Education Materials!